Industry News

Diplomat Pharmacy reported on Monday that it is filling prescriptions for ZINBRYTA for the treatment of adult patients with relapsing forms of multiple sclerosis. The company added that ZINBRYTA has been approved by the US Food and Drug Administration. ZINBRYTA is an interleukin-2 receptor-blocking antibody indicated for the treatment of adult patients with relapsing forms of multiple sclerosis."/>
Diplomat to distribute ZINBRYTA for the treatment of adult patients with relapsing forms of multiple sclerosis
China Cord Blood Corporation today announced that it plans to release financial results for the first quarter of fiscal year 2017 on Monday, August 22, 2016, after market close. The Company will host a conference call at 8:00 a.m. ET on Tuesday, August 23, 2016 to discuss its financial performance and give a brief overview of the Company's recent developments, followed by a question and answer session. Interested parties can access the audio..."/>
China Cord Blood Corporation to Report First Quarter of Fiscal 2017 Financial Results
UnitedHealth Group, are taking immediate action to help people in Louisiana and Mississippi who may be affected by the recent flooding. This includes assisting health plan participants who may need to make alternate arrangements to ensure continuity of care and access to early prescription refills, as well as a free emotional-support line to help people in affected communities."/>
UnitedHealthcare and Optum Support People Affected by Floods in Louisiana and Mississippi
Baxter International Inc. will present at the Morgan Stanley Global Healthcare Conference on Monday, September 12 in New York. Jose E. Almeida, chairman and chief executive officer is scheduled to present at 3:15 p.m.. The live webcast of Baxter's presentation can be accessed at and will be available for replay through December 12, 2016.."/>
Baxter to Present at the Morgan Stanely Global Healthcare Conference
Arena Pharmaceuticals reported on Monday the election of Vincent Aurentz as its executive vice president and chief business officer. Effective immediately, Aurentz will report to the company's president and chief executive officer, Amit Munshi. Most recently, Aurentz has served as the chief business officer of Epirus Biopharmaceuticals."/>
Arena Pharmaceuticals names Vincent Aurentz as chief business officer
CombiMatrix Corporation, a family health molecular diagnostics company specializing in DNA-based reproductive health and pediatric testing services, notes that Health Care Service Corporation has issued a medical policy to include reimbursement for chromosomal microarray analysis for the evaluation of pregnancy loss. HCSC is the largest customer-owned health insurance company in the United States. HCSC operates through Blue Cross and Blue..."/>
CombiMatrix Notes Decision by Health Care Service Corporation to Reimburse for Recurrent Pregnancy Loss Testing
Interpace Diagnostics Group, a company that provides clinically useful molecular diagnostic tests and pathology services for evaluating risk of cancer by leveraging the latest technology in personalized medicine for better patient diagnosis and management, today reported financial and operational results for the second quarter ended June 30, 2016.. Net revenue for the second quarter of 2016 was $3.6 million, a significant..."/>
Interpace Diagnostics Reports Record Revenue and Cash Collections for the 2016 Second Quarter
Ritter Pharmaceuticals revealed on Monday the completion of patient enrolment on schedule under its Phase 2 b/3 clinical trial of its investigational compound RP-G28 for the treatment of lactose intolerance. In conjunction with the enrolment, the company expects the topline results of the trial to be announced in the first quarter of 2017.. This double-blind, placebo-controlled, three arm, multicentre Phase 2 b/3 trial is evaluating the safety,..."/>
Ritter Pharmaceuticals concludes patient admission under Phase 2b/3 Trial of RP-G28 in lactose intolerance condition
China Biologic Products announced on Monday the resignation of Min Fang from its board of directors with immediate effect. Currently, Fang is the director associated with Warburg Pincus LLC, a global private equity firm. Warburg Pincus entities have reportedly reduced their holdings in China Biologic Products over the last year in the ordinary course of their investing business and now hold less than 0.1% of China Biologic Products' outstanding common stock."/>
China Biologic reports departure of board director Min Fang
Vital Therapies revealed on Monday the addition of Faheem Hasnain to its board of directors with immediate effect. Concurrent with the board appointment, Hasnain has made a personal investment in shares of the company. Most recently, Hasnain has worked as the president, CEO and director at Receptos from November 2010 to August 2015.."/>
Vital Therapies elects Faheem Hasnain to board
Sunshine Heart, Inc. announced today the appointment of Megan Brandt to the position of Vice President of Regulatory Affairs and Quality Assurance. Brandt will facilitate and manage quality and regulatory affairs for Sunshine Heart.. “Megan brings to the company a specific set of necessary skills to successfully guide us through the regulatory approval process as we push forward in our new clinical strategy,” said John Erb, Chairman and Chief..."/>
Sunshine Heart Appoints Megan Brandt as Vice President, Regulatory Affairs and Quality Assurance
Emergent BioSolutions reported on Monday the receipt of US Food and Drug Administration approval for its supplemental Biologics License Application for the manufacture of BioThrax in Building 55 in Lansing, Michigan. According to the company, the Building 55 is its large-scale manufacturing facility located in its 12.5- acre campus in Lansing, Michigan. The company said the BioThrax programme was executed under contract HHSO100201000034C,..."/>
Emergent BioSolutions wins US FDA approval for Building 55 for large-scale manufacturing of BioThrax
Aratana Therapeutics revealed on Monday that it has received approval from the US Food and Drug Administration Center for Veterinary Medicine for NOCITA as a local post-operative analgesia for cranial cruciate ligament surgery in dogs. In conjunction with the US FDA approval, the company expects Nocita to be commercially available to veterinarians in the fall of 2016.. The company added that Nocita is a long-acting, local anesthetic that lasts up..."/>
Aratana Therapeutics awarded US FDA approval for NOCITA for control post-operative pain in dogs
Recro Pharma said on Tuesday that it plans to issue and sell shares of its common stock in an underwritten public offering. All of the shares in the offering will be sold by the company. Net proceeds of the planned offering may be used by the comany to fund its ongoing Phase III pivotal clinical trial and safety studies of injectable meloxicam as well as for general corporate purposes."/>
Recro Pharma to launch public offering of common shares
Natco Pharma Ltd rose 1.06% to Rs.640.55 at noon on Tuesday as the company announced that it has successfully closed the US Food and Drug Administration inspection at its main formulation facility. "Natco Pharma is pleased to announce successful establishment inspection report from the USFDA," the company said in a statement to the stock exchanges. The company's Kothur facility near Hyderabad that predominantly caters to regulated international..."/>
Natco Pharma shares gain after USFDA clearance for Kothur plant [Mint, New Delhi]
Centene Corp. that would add office space and parking spots for thousands more workers in this city's downtown business district. For almost three hours, speakers took to the microphone at Clayton High School to weigh in on Centene's plans, most of them concerned about increased traffic and density in the fast-growing suburb. "This is outrageous, and we're not talking about the tax credits,"..."/>
Clayton residents speak out against Centene campus expansion [St. Louis Post-Dispatch]
Immunicum AB announces change of the financial calendar
Concordia International Corp.. Investors who purchased or otherwise acquired shares between November 12, 2015 and August 12, 2016 inclusive are encouraged to contact the Firm in advance of the October 14, 2016 lead plaintiff motion deadline. If you are a shareholder who suffered a loss during the Class Period, click here to participate."/>
INVESTOR NOTICE: Goldberg Law PC Announces Securities Class Action Lawsuit against Concordia International Corp. and Encourages Investors with Losses to Contact the Firm
Mazor Robotics Ltd. (Nasdaq: MZOR; reported today that global medical equipment company Medtronic had made a $20 million milestone payment for a 3.4% stake in the company as part of its strategic agreement. The investment follows the launch of Mazor X, a high precision spinal surgery guidance system, which will be jointly marketed by the companies. Medtronic also had the option of buying 6% of the company's shares but chose to make the..."/>
BRIEF: Medtronic makes $20m milestone investment in Mazor [Globes, Tel Aviv, Israel]
Aetna Inc. announced Monday that it's scaling back its participation in Obamacare by more than two-thirds as it seeks to cut its financial losses. The Hartford-based health insurer said Monday night it will reduce its participation in health care exchanges next year to 242 counties from 778. The company said it took a second-quarter pretax loss of $200 million and total pretax losses of more than $430 million since 2014 in individual plans."/>
Aetna Cuts Its Obamacare Coverage By Two-Thirds [The Hartford Courant]

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Most Popular Sectors in the News
Sectors Articles in the last 7 days
Consumer Discretionary692 Articles
Information Technology661 Articles
Financials551 Articles
Health Care400 Articles
Industrials385 Articles

Sponsored Financial Commentaries

Request Profile Update

Only a company representative may request an update for the company profile. Documentation will be required.

To contact , please visit . Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at